ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation

ALX Oncology Holdings Inc ALXO presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome. 

  • The new results were shared at the 63rd American Society of Hematology (ASH).
  • Evorpacept combined with azacitidine was well tolerated (N=22) with no dose-limiting toxicities, no treatment-related serious adverse events were observed, and a maximum administered dose of 60 mg/kg Q4W.
  • In 6 high-risk response-evaluable patients, three patients achieved an objective response (two complete responses and one marrow CR), and two patients achieved stable disease. 
  • Two out of 4 transfusion-dependent patients achieved transfusion independence in the study.
  • Among five previously untreated high-risk patients with TP53 mutation and complex cytogenetic abnormalities, 3 achieved an OR (2 CR and 1 marrow CR).
  • Price Action: ALXO shares are trading 25.6% lower at $23.12 during the market session on the last check Monday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralASH21Briefsmyelodysplastic syndromePhase 1 TrialPhase 2 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!